Maze Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	2.5	167.5	-	-
Gross Profit	2.5	167.5	-	-
Selling, General & Admin	30.57	26.42	24.61	22.83
Research & Development	97.76	83.5	73.95	88.19
Operating Expenses	128.33	109.91	98.55	111.03
Operating Income	-125.83	57.59	-98.55	-111.03
Interest & Investment Income	8.77	4.65	1.97	2.03
Earnings From Equity Investments	-	-	-	-3.54
EBT Excluding Unusual Items	-117.06	62.24	-96.59	-112.54
Gain (Loss) on Sale of Investments	-	-	-	-2.4
Other Unusual Items	-4.29	-8.84	-3.83	-
Pretax Income	-121.35	53.4	-100.42	-114.94
Income Tax Expense	-0.55	1.17	-	-
Net Income	-120.8	52.23	-100.42	-114.94
Preferred Dividends & Other Adjustments	-47	48.83	-	-
Net Income to Common	-73.8	3.41	-100.42	-114.94
Shares Outstanding (Basic)	19	2	2	2
Shares Outstanding (Diluted)	19	3	2	2
Shares Change (YoY)	727.28%	19.33%	13.82%	-
EPS (Basic)	-3.82	1.42	-43.89	-57.18
EPS (Diluted)	-3.82	1.25	-43.89	-57.18
Free Cash Flow	-106.63	74.81	-87.27	-101.17
Free Cash Flow Per Share	-5.51	27.40	-38.14	-50.33
Gross Margin	100.00%	100.00%	-	-
Operating Margin	-5033.20%	34.38%	-	-
Profit Margin	-2951.92%	2.03%	-	-
Free Cash Flow Margin	-4265.00%	44.66%	-	-
EBITDA	-123	60.88	-94.46	-107.21
EBITDA Margin	-	36.35%	-	-
D&A For EBITDA	2.83	3.3	4.09	3.82
EBIT	-125.83	57.59	-98.55	-111.03
EBIT Margin	-	34.38%	-	-
Effective Tax Rate	-	2.20%	-	-

Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q